Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility

Chinese Medical Journal

Volumn 122, Issue 13, 2009, Pages 1585-1586

  Liu, Yan ^a   Wang, Chun Mei ^a   Cheng, Jun ^b   Liang, Zhao Ling ^a   Zhong, Yan Wei ^a   Ren, Xiao Qiang ^a   Xu, Zhi Hui ^a   Zoulim, Fabien ^c   Xu, Dong Ping ^a  

^a BEIJING 302 HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c INSERM   (France)

Author keywords

Drug resistance; Hepatitis B virus; Mutation; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE; ASPARAGINE; ENTECAVIR; GLUTAMINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; SERINE; TELBIVUDINE; TENOFOVIR; THREONINE; VALINE; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHINESE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENOMIC FRAGMENT; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENE AMPLIFICATION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 70349559554     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.13.021     Document Type: Article

References (9)

1. Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J 2007; 120: 2157-2158.
2. Margot NA, Lu B, Cheng A, Miller MD. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006; 7: 442-450.
3. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734.
4. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positve and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49: 1158-1165.
5. Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-2477.
6. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78 Suppl 1: s52-s55.
7. Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-362.
8. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-755.
9. Leemans WF, Janssen HL, Niesters HG, de Man RA. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008; 15: 108-114.